How has CRISPR changed drug development? How do you negotiate a good partnership? What are some of the hard decisions to make in founding a biotech? These are some of the questions that industry experts answered at Labiotech’s first Insider Day.
Held exclusively for members, Labiotech’s first Insider Day aimed to explore the different aspects of growing a biotech company. Experts from a wide variety of backgrounds including biotech companies and VC firms discussed key questions on the minds of everyone in the biotech industry such as building the best partnership and how to navigate the founding process.
CRISPR’s impact on the biotech industry
Rodger Novak, President and co-founder of CRISPR Therapeutics
The gene editing tool CRISPR/Cas9 is making it easier than ever to precisely tweak DNA code and correct mutations, showing enormous potential in therapeutics. While many labs today could not work without CRISPR, it was a challenge to build a company around it back when the technology was still new.
The day’s first speaker, Rodger Novak is the President and co-founder of CRISPR Therapeutics, a Swiss biotech that licenses CRISPR technology to commercial partners for use in human therapeutics. According to Novak, it was difficult in the beginning to find investors that understood the best business plan for the technology.